Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT02464228 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT02464228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02464228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 25, 2016
Completion date
March 31, 2021
Enrollment
65 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory peripheral t-cell lymphoma